

NEOTIGHT™ EYE SERUM

Brighter- looking eyes, with visible results that deepen over time.

Expert grading documented significant Week 6 improvements across dark circles, puffiness, and peri-orbital lines - a focused visible-results story for the delicate eye area.



33 completed 6 weeks Expert graded VCS sample SA211001 SGF20117-01

38.10%
mean improvement in dark-circle appearance
 WEEK 6
 Expert grading, n=33; p<0.001.

23.12%
mean improvement in puffiness and bags
 WEEK 6
 Expert grading, n=33; p<0.001.

100%
said the delicate eye area felt nourished
 WEEK 6
 Participant perception, n=33.

RESULTS THAT BUILD

Visible improvement progressed through Week 6.

Dark circles / discoloration 38.10%




Expert-graded mean improvement; n=33; p<0.001.

Puffiness / bags 23.12%



Expert-graded mean improvement; n=33; p<0.001.

Peri-orbital fine lines 8.82%



Expert-graded mean improvement; n=31; p<0.001.

Selected Week 6 participant perceptions

93.94%

reported increased smoothness.

93.94%

agreed the lightweight texture absorbed quickly, leaving skin soothed and refreshed.

84.85%

saw brighter-looking dark circles.

84.85%

saw improved bags and puffiness.

75.76%

saw improved-looking fine lines.

78.79%

saw improved eyelid crepiness.

Participant percentages are self-reported agreement. Immediate instrument effects and long-term expert appearance grading are distinct evidence classes.

IMMEDIATE PERFORMANCE

Fifteen minutes after the first application, Cutometer readings showed an 8.31% improvement in R0 firmness (n=27; p=0.039) and a 15.16% improvement in R5 elasticity (n=27; p=0.001). These immediate instrument findings are presented separately from the Week 4 and Week 6 expert-graded appearance results.

TECHNICAL STUDY RECORD

A signed final source supports the visible eye-area story.

INDEPENDENT LABORATORY Validated Claim Support, LLC	STUDY / REPORT CS201061 / RE201061.V01
TESTED ARTICLE NeoTight Revitalizing Eye Serum SA211001 / SGF20117-01	DESIGN 6-week single-arm study with 7-day washout
POPULATION 37 enrolled; 33 completed; ages 36-69	USE Twice daily around the eye area
EVIDENCE Expert grading, Cutometer, photography, questionnaire	SOURCE DATE 8 April 2021

Expert-graded mean change from baseline

Expert endpoint	15 minutes	Week 4	Week 6
Dark circles / discoloration	-10.20%; n=33; p<0.001	-31.95%; n=32; p<0.001	-38.10%; n=33; p<0.001
Puffiness / bags	-8.67%; n=33; p<0.001	-16.55%; n=32; p<0.001	-23.12%; n=33; p<0.001
Peri-orbital fine lines	-1.18%; n=31; p=0.161	-4.57%; n=30; p=0.001	-8.82%; n=31; p<0.001

Lower grades indicate improvement. n is shown for every endpoint and timepoint.

Instrumental timing context

Cutometer parameter	15 minutes	Week 4	Week 6
R0 firmness	-8.31%; p=0.039	+32.00%; p<0.001	+35.17%; p<0.001
R5 elasticity	+15.16%; p=0.001	-15.74%; p<0.001	-12.04%; p=0.005

R0 decrease and R5 increase indicate improvement. The favorable Cutometer response was recorded at 15 minutes; Week 4 and Week 6 values are included for complete timing context.

STUDY CONTEXT

Thirty-three participants completed the study. Two mild adverse events were recorded and no participant withdrew. Results apply to NeoTight Revitalizing Eye Serum SA211001 / SGF20117-01 under the reported six-week design.



INDEPENDENT LABORATORY EVIDENCE

Original source pages follow.

Selected original VCS pages follow, preserving the study summary, methods, complete aggregate questionnaires, conclusion, authorization, and Quality Assurance evidence. Expert-grade and Cutometer results are reproduced in aggregate on the preceding technical page; participant-level listings are excluded.

LABORATORY Validated Claim Support, LLC	STUDY / REPORT CS201061 / RE201061.V01
SOURCE DATE 8 April 2021	AUTHENTICATION Dated electronic authorizations + QA/QC

SOURCE AUTHENTICATION

The source contains dated authorization from Principal Investigator Anna Hardy, review by Medical Investigator David A. Wrone, M.D., and independent QA/QC certification dated 9 April 2021.

SOURCE NOTE

Participant identifiers and participant-level measurement rows were removed from the appended result pages; aggregate mean, p-value, and t-value results are unchanged. Week 4 expert endpoint n=30 is used in the summary.

Independent laboratory source pages are included in the complete PDF. Participant-identifying information has been removed where indicated; aggregate findings are unchanged.



STUDY REPORT

1. Report Summary:

Study Title:	6 Week Evaluation of an Eye Product
Sponsor:	SeneGence 19651 Alter Foothill Ranch, California 92610
Test Article:	Neotight Revitalizing Eye Serum
VCS Sample No.:	SA211001
VCS Clinical Study No.:	CS201061
Study Initiation Date:	21 January 2021
Study Completion Date:	12 March 2021
Subjects Reported:	29-33
Version:	FINAL
Study Location:	Validated Claim Support, LLC 400 Frank W. Burr Boulevard Suite 105 Glenpointe Atrium Teaneck, New Jersey 07666
Study Design:	Test product was evaluated at 15 Minutes, 8 Hours, Week 4 and Week 6 using Qualitative Questionnaire, Expert Grading, as well as Instrumental measurements via Cutometer, and Clinical Photography (Subset of 5).

2. Key Study Personnel and Responsibilities:

Principal Investigator:	Anna Hardy
Clinical Photographer:	James VanZetta
Technicians:	Chrystal Planeta & Surina Chock
Dermatologist:	David A. Wrone, M.D.

3. Introduction and Objective:

This panel was convened to evaluate the efficacy of a test material intended to improve under eye skin conditions such as discoloration/dark circles, puffiness/bags, and fine lines and wrinkles (peri-orbital) as well as its ability to improve the firmness of under eye skin over a period of 6 weeks.

4. Safety Prerequisite:

Sponsor purports that toxicology, microbiology, preservative efficacy, and/or other in-vitro/in-vivo safety and performance analyses were conducted as required by law or as recommended by legal counsel and that the test article does not contain antibiotics, antiseptics, steroids, hormones, or any other substances at levels of concentration requiring label declaration by the relevant regulatory authorities.

5. Selection of Subjects:

5.1. Screening

Subject Status	Number
Subjects Enrolled	37
Subjects Completed (See Panelist Demographics – Appendix 1)	33
Subjects Reported	29-33

All subjects enrolled into the study completed VCS required documentation, have been assigned an MRN (Medical Record Number, a unique identification number), satisfied the study specific inclusion and exclusion criteria, and gave their written informed consent.

5.1. Inclusion Criteria

- Female and/or Male subjects in good general health, aged 30-70 years old, that identify as one or more of the following:
 - Caucasian
 - Asian
 - Black/African American
 - American Indian/Alaska Native
 - Native Hawaiian/Pacific Islander
 - Hispanic
 - Individuals who qualify with a minimum of one of the following at Baseline*:
 - Under-eye discoloration/dark circles, score of ≥ 1 on 5-point ordinal scale
 - Under-eye puffiness, score of ≥ 1 on 5-point ordinal scale
 - Fine lines/wrinkles in the peri-orbital area, score of ≥ 2 on 5-point ordinal scale
- *Attempts will be made to enroll subjects with all 3 conditions. If the condition is not present, it will not be graded.
- Individuals who are able to cooperate with the Principal Investigator and study personnel throughout the duration of the study and are willing to comply with all study procedures, methods, evaluations, and study product use.
 - Individuals who are able to read, understand and willing to sign an informed consent for this specific study and have completed all VCS required documentation prior to study enrollment (Registration and Medical History).
 - Individuals willing to be photographed and sign a model release.

5.2. Exclusion Criteria

- Individuals with acute or chronic disease(s) or medical condition(s), including dermatological problems, which could put them at risk in the opinion of the Principal Investigator or compromise the study outcome. Typical uncontrolled chronic or serious diseases and conditions which would prevent participation in any clinical study are cancer, AIDS, insulin dependent diabetes, renal impairment, mental illness, and/or drug/alcohol addiction.
- Individuals with a history of melanoma, or a treated skin cancer within the last 5 years.
- Individuals who are pregnant, lactating, or planning to become pregnant. Individuals who become pregnant during the study must inform the Principal Investigator immediately.
- Individuals who are unreliable or unlikely to be available for the duration of the study.
- Individuals with a history of allergic reactions, skin sensitization and/or known allergies to cosmetic and personal care products/ingredients.
- Individuals who are immunocompromised.

- Individuals who are employees of VCS or other testing firms/laboratories, cosmetic or raw goods manufacturers or suppliers.
- Individuals who are unable to communicate or cooperate with the Principal Investigator/study personnel due to language problems, poor mental development, or impaired cerebral function.
- Individuals who started Hormone Replacement Therapy within the last three months preceding the commencement of the study.
- Individuals who are using oral contraception for less than three months before study commencement or who have changed their contraceptive method within the three months before the Baseline visit or planning to modify their contraception treatment within the duration of the study.
- Individuals who have regular salon and/or dermatological procedures that can interfere with study results (Eyelash extensions, Eyebrow Microblading, Microdermabrasion, Fillers, Facial Peels, etc.) and are not willing to stop throughout the study.
- Individuals or any immediate family/household members who have travelled (domestically or internationally) outside of their normal routine 2 weeks prior to the screening visit and throughout the study.
- Individuals with COVID-19 related symptoms (fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and/or diarrhea) within 2 weeks prior to the screening visit and throughout the study.
- Individuals who have used a fever/pain reducer within 24 hours prior to any site visit.

5.3. Prohibitions & Restrictions for the Duration of the Study

- Excessive/direct sun exposure for the purpose of tanning during the study.
- Use of self-tanning products or tanning beds during the study.
- Initiating the use of any new cosmetic/personal care products during the study.
- Using other topical products in the eye area during the study.

6. Institutional Review Board:

IRB approval was not requested by the sponsor.

7. Study Procedure:

This was a 6 Week study of the performance of one test product. A seven-day washout period preceded the evaluation period. All subjects used the test product each day per Sponsor instructions. At least 30 subjects were expected to complete the study. Changes in skin condition was assessed by expert clinical grading, instrumental assessments and clinical photography. Consumer perception of the product and its effects was determined from subjective questionnaire results.

Evaluation points occurred pre-application (Baseline), immediately post-initial-application (T15m) and after four and six weeks of use. A detailed outline of study visits appears in Section 10.

8. Test Product:

Upon reception of samples at VCS, the test material was assigned a unique code and digitally logged into the system. Products were stored in a secure location and unused products were returned to Sponsor or discarded upon issue of final report.

8.1. Use Instructions

Use twice a day morning and night. Gently pat around the eye area, including eye lid. Avoid direct contact with eyes.

9. Methodology:

9.1. Assessments

The devices used for this study are non-invasive and have no known risks associated with them.

9.1.1 Qualitative Questionnaire

All participants were asked to complete a qualitative questionnaire, pertaining to product use, and provide information about product effectiveness. A questionnaire was completed approximately 8 hours after the first application (at-home) and onsite at Weeks 4 and 6.

No.	Question	Agree	Disagree	N/A
1	The test product visibly brightened my dark under-eye circles.			
2	The test product visibly improved the look of my under-eye bags and puffiness.			
3	The test product increased smoothness around eye area.			
4	The test product made my tired-looking eyes look more energized.			
5	The test product's light-weight texture absorbed quickly, leaving skin soothed and refreshed.			
6	The test product improved the look of fine lines and wrinkles around my eyes.			
7 *	The test product quickly smoothed and tightened the skin under my eyes.			
8 *	The test product instantly minimized the appearance of fine lines and wrinkles.			
9 *	The test product effects lasted up to 8 hours.			
10 *	The test product lasted all day.			
11	The test product smoothed my skin for a filter-like look.			
12	The test product helped my eyes feel less tired and more energetic.			
13	The test product reduced the appearance of crow's feet.			
14	The test product reduced the appearance of sagging eyelids.			
15	The test product reduced the appearance of dark circles.			
16	The test product reduced the appearance of eye bags.			
17	The test product increased the luminosity of my skin.			
18	The test product nourished the delicate skin around my eyes.			
19	The test product lifted and defined my eye contours.			
20	The test product improved the look of my eyelid crepiness.			
21	The test product appeared to "fill in" my fine lines and wrinkles.			

*8 Hour only

9.1.2 Expert Grading

All subjects had the eye area and peri-orbital skin assessed by an expert grader at Baseline, 15 Minutes, Week 4 and Week 6 utilizing a 10-point ordinal scale.

Clinical grading was performed in the same room at each study visit using overhead lighting as well as a lighted magnifying loop as needed. Natural sunlight was blocked from the room to ensure the same lighting conditions at each time point.

The following 5-point ordinal scales (including half point increments) was used:

Under-Eye Discoloration/Dark Circles	
Grade	Description
0	No color difference from surrounding skin
1	Mild, faint color difference, weak intensity (light brown)
2	Moderate color difference and intensity (light brown/ tan color)
3	Moderate/ Deep color difference (brown/ tan)
4	Intense/ Deep color difference (dark brown/ tan)
Under-Eye Puffiness/Bags	
Grade	Description
0	None, Smooth appearance under eye
1	Mild
2	Moderate
3	Moderate/Severe
4	Severe, pronounced bags, puffy appearance
Fine Lines/Wrinkles (Peri-Orbital)	
Grade	Description
0	Absence of fine lines
1	Slightly visible fine lines
2	Clearly visible fine lines and/or wrinkles
3	Prominent wrinkles
4	Deep, Severe lines wrinkles

9.1.3 Cutometer® Dual MPA 580


The Cutometer MPA 580 (Courage + Khazaka, Germany) measures the viscoelastic properties of the skin by applying suction to the skin surface, drawing the skin into the aperture of the probe and determining the penetration depth using an optical measuring system.

The resistance of the skin to be sucked up by the negative pressure (firmness) and its ability to return to its original position (elasticity) are calculated and displayed as curves. The Cutometer outputs include many parameters of different portions of the measurement curve including of R0 (Uf, firmness), R2 (Ua/Uf, gross elasticity), R5 (Ur/Ue, net elasticity), R7 (Ur/Uf, elastic portion) and R9 (R3[last max amp]-R0[Uf], fatigue).

Elasticity was reported using the R5 (Ur/Ue) parameter, as the skin becomes more elastic this value will increase. Skin Firmness was reported using the R0 (Uf) parameter, as the skin becomes firmer this value will decrease.

Ref. COURAGE + KHAZAKA electronic GmbH, Cutometer Dual MPA 580, February 2019

Two measurements from either the left or ride side (based on randomization) were taken from each test subject according to following template:



9.1.4 Validated Clinical Photography

Validated Clinical Photography involves a fully controlled, high resolution image capture process of multiple timepoints throughout a given treatment or product use regimen. Angles are measured and recorded, equipment placement is either permanent (bolted down) or measured and recorded at each time point. All photographs are taken in a temperature-controlled environment with no natural/ambient light. Panelists are guided throughout the process by a professional photographer and/or a clinical technician.

Images are “stripped” (cropped, aligned, and put into side by side format) but otherwise unedited and unretouched. Images are taken from the best representative angles as determined by study team. Measurements are taken from the images by means of a volumetric pixel count and analyzed.

Photography was conducted on a subset of 5 subjects. Analysis of under-eye dark circles, puffiness and peri-orbital fine lines/wrinkles was performed on most improved area and was provided as stated above (at least 1 parameter per subject).

10. Procedure

All panelists arrived with a clean face, free from any cosmetic, facial, or test product(s) for each study evaluation. Panelists were instructed to remove all make up the night before each evaluation visit. Panelists arrived for each evaluation after washing their face in the morning with their regular face wash. Panelist were instructed not to use the test product, any other cosmetic or facial products on evaluations days.

At the screening visit, panelists were given washout instructions to be used for the 7 days leading up to the Baseline visit.

On Day 0 (Baseline), panelists washed their face, including eye area, with Cetaphil onsite and acclimate for a minimum of 15 minutes prior to any visit procedures. Upon completion of all Baseline procedures, panelists applied the test product for the first time onsite under supervision of study personnel. After 15 minutes, all study procedures were performed. All panelists were given a questionnaire to be filled out at home, approximately 8 hours after product application.

At each visit (Week 4 and week 6), following acclimation, all study procedures were performed, and product was weighed and collected on the final visit.

12. Withdrawals

The participation of a subject in this study may have been discontinued for any of the following reasons:

- If the subject wishes to withdraw, they may do so at any time
- If in the opinion of the Principal Investigator, it is in the best interest of the subject
- Suspected adverse effects from test articles
- Inter-current illness
- Violation of prohibitions and restrictions
- Development of an exclusion criterion

Subjects were free to withdraw at any time and need not give a reason and every reasonable attempt is made to ascertain such reasons. The subjects who withdrew from the study are excluded from final data analysis.

There were no withdrawals reported in the study.

12.1. Internal Statistical Method

Data Type	Statistical Method	Data Reported
Demographics	Descriptive Statistics	Mean, Min and Max, Frequency (Number & Percent)
Instrumental Assessments	Descriptive Statistics Paired T-Test (Subsequent vs. Baseline)	Mean, Mean percent improvement, Percent subjects improved, P-value
Expert Grading	Descriptive Statistics	Grade frequency (Percent), Mean, Mean percent improvement
Qualitative Questionnaire	Descriptive Statistics	Response frequency (Percent)

13. Modifications to Protocol:

13.1. Amendments

There were no amendments to the protocol.

designated as a high consequence infectious disease (HCID) but still requires a national, coordinated response. For most people, COVID-19 will be a mild illness but may result in pneumonia or severe acute respiratory infection for some people.

VCS has developed new safety procedures that follow all federal and local requirements and regulations and have implemented a number of additional recommendations to reduce the risk of transmission of this novel virus as described in VCS Standard Operating Procedure (SOP-017).

15.3. Informed Consent Form Process

A study-specific informed consent is obtained from each volunteer prior to initiating the study indicated herein, it describes the design, reasons for study, possible adverse effects, associated risks and potential benefits of treatment and their limits of liability. Subjects sign and date the informed consent document to indicate their authorization to proceed and acknowledge their understanding of the contents. Subjects are informed that they are free to withdraw from the study at any time without being obliged to give a reason. Reference 21 CFRCh.1 Part 50, Subpart B.

15.4. Declaration of Helsinki

The study conformed to the requirements of the Declaration of Helsinki and its subsequent amendments (*World Medical Association; 2013*).

15.5. Indemnity Provision

The Sponsor is responsible, without regard to legal liability, and indemnifies VCS, or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury or other deterioration in health or wellbeing as a result of participation in this study. An exception can occur when claims arise as a result of any negligent act or omission on the part of VCS employees or any persons undertaking or involved in the study by arrangement with VCS.

Prior to commencement of this in-vivo clinical study with VCS an indemnification agreement was signed by the sponsor.

16. Retention of Data:

All raw data generated by VCS during the course of the study, and including protocol and final report, is retained digitally by VCS for a period of 25 years as per regulatory guidelines.

Data is secured on premise and through cloud-based backups in confidence, and shared only with sponsor clients, regulatory bodies, and AIRB upon request.

17. Results:

Questionnaire Summary 8 Hour (N=32)				
No.	Question	Agree	Disagree	N/A
1	The test product visibly brightened my dark under-eye circles.	50.00%	43.75%	6.25%
2	The test product visibly improved the look of my under-eye bags and puffiness.	68.75%	28.13%	3.13%
3	The test product increased smoothness around eye area.	81.25%	15.63%	3.13%
4	The test product made my tired-looking eyes look more energized.	68.75%	28.13%	3.13%
5	The test product's light-weight texture absorbed quickly, leaving skin soothed and refreshed.	84.38%	15.63%	0.00%
6	The test product improved the look of fine lines and wrinkles around my eyes.	56.25%	37.50%	6.25%
7	The test product quickly smoothed and tightened the skin under my eyes.	75.00%	21.88%	3.13%
8	The test product instantly minimized the appearance of fine lines and wrinkles.	50.00%	40.63%	9.38%
9	The test product effects lasted up to 8 hours.	71.88%	28.13%	
10	The test product lasted all day.	56.25%	43.75%	
11	The test product smoothed my skin for a filter-like look.	59.38%	40.63%	0.00%
12*	The test product helped my eyes feel less tired and more energetic.	74.19%	25.81%	0.00%
13	The test product reduced the appearance of crow's feet.	50.00%	43.75%	6.25%
14	The test product reduced the appearance of sagging eyelids.	56.25%	37.50%	6.25%
15	The test product reduced the appearance of dark circles.	56.25%	40.63%	3.13%
16	The test product reduced the appearance of eye bags.	65.63%	28.13%	6.25%
17	The test product increased the luminosity of my skin.	71.88%	25.00%	3.13%
18	The test product nourished the delicate skin around my eyes.	81.25%	15.63%	3.13%
19	The test product lifted and defined my eye contours.	40.63%	59.38%	0.00%
20	The test product improved the look of my eyelid crepiness.	56.25%	31.25%	12.50%
21	The test product appeared to "fill in" my fine lines and wrinkles.	53.13%	40.63%	6.25%

*Missing 1 response (N=31)

Questionnaire Summary 4 Week (N=32)				
No.	Question	Agree	Disagree	N/A
1	The test product visibly brightened my dark under-eye circles.	71.88%	28.13%	0.00%
2	The test product visibly improved the look of my under-eye bags and puffiness.	68.75%	28.13%	3.13%
3	The test product increased smoothness around eye area.	96.88%	3.13%	0.00%
4	The test product made my tired-looking eyes look more energized.	78.13%	21.88%	0.00%
5	The test product's light-weight texture absorbed quickly, leaving skin soothed and refreshed.	93.75%	6.25%	0.00%
6	The test product improved the look of fine lines and wrinkles around my eyes.	68.75%	25.00%	6.25%
7	The test product smoothed my skin for a filter-like look.	68.75%	28.13%	3.13%
8	The test product helped my eyes feel less tired and more energetic.	75.00%	21.88%	3.13%
9	The test product reduced the appearance of crow's feet.	65.63%	25.00%	9.38%
10	The test product reduced the appearance of sagging eyelids.	50.00%	37.50%	12.50%
11	The test product reduced the appearance of dark circles.	71.88%	28.13%	0.00%
12	The test product reduced the appearance of eye bags.	68.75%	25.00%	6.25%
13	The test product increased the luminosity of my skin.	84.38%	12.50%	3.13%
14	The test product nourished the delicate skin around my eyes.	93.75%	6.25%	0.00%
15	The test product lifted and defined my eye contours.	56.25%	43.75%	0.00%
16	The test product improved the look of my eyelid crepiness.	68.75%	21.88%	9.38%
17	The test product appeared to "fill in" my fine lines and wrinkles.	65.63%	28.13%	6.25%

Questionnaire Summary Week 6 (N=33)				
No.	Question	Agree	Disagree	N/A
1	The test product visibly brightened my dark under-eye circles.	84.85%	15.15%	0.00%
2	The test product visibly improved the look of my under-eye bags and puffiness.	84.85%	12.12%	3.03%
3	The test product increased smoothness around eye area.	93.94%	6.06%	0.00%
4	The test product made my tired-looking eyes look more energized.	84.85%	15.15%	0.00%
5	The test product's light-weight texture absorbed quickly, leaving skin soothed and refreshed.	93.94%	6.06%	0.00%
6	The test product improved the look of fine lines and wrinkles around my eyes.	75.76%	15.15%	9.09%
7	The test product smoothed my skin for a filter-like look.	72.73%	27.27%	0.00%
8	The test product helped my eyes feel less tired and more energetic.	81.82%	18.18%	0.00%
9	The test product reduced the appearance of crow's feet.	66.67%	27.27%	6.06%
10	The test product reduced the appearance of sagging eyelids.	63.64%	33.33%	3.03%
11	The test product reduced the appearance of dark circles.	69.70%	30.30%	0.00%
12	The test product reduced the appearance of eye bags.	66.67%	24.24%	9.09%
13	The test product increased the luminosity of my skin.	87.88%	12.12%	0.00%
14	The test product nourished the delicate skin around my eyes.	100.00%	0.00%	0.00%
15	The test product lifted and defined my eye contours.	66.67%	30.30%	3.03%
16	The test product improved the look of my eyelid crepiness.	78.79%	12.12%	9.09%
17	The test product appeared to "fill in" my fine lines and wrinkles.	66.67%	27.27%	6.06%

Expert Grading Summary					
Parameter 1: Under Eye Discoloration/Dark Circles (N=33)					
Grading Scale		Grade Frequency			
		Baseline	Immediate	Week 4**	Week 6
0.0	No color difference from surrounding skin	0.00%	0.00%	6.25%	6.06%
0.5		0.00%	3.03%	6.25%	15.15%
1.0	Mild, faint color difference, weak intensity (light brown)	9.09%	21.21%	28.13%	30.30%
1.5		18.18%	12.12%	21.88%	12.12%
2.0	Moderate color difference and intensity (light brown/tan)	24.24%	24.24%	25.00%	27.27%
2.5		24.24%	21.21%	6.25%	3.03%
3.0	Moderate/Deep color difference (brown/tan)	18.18%	15.15%	3.13%	3.03%
3.5		3.03%	0.00%	0.00%	3.03%
4.0	Intense/Deep color difference (dark brown/tan)	3.03%	3.03%	3.13%	0.00%
Mean Score		2.2	2.0	1.5	1.4
Mean % Change			-10.20%	-31.95%	-38.10%
		p	0.000*	0.000*	0.000*
		t	5.164	8.824	10.619
Parameter 2: Under Eye Puffiness/Bags (N=33)					
Grading Scale		Grade Frequency			
		Baseline	Immediate	Week 4**	Week 6
0.0	None, Smooth appearance under eye	0.00%	0.00%	0.00%	0.00%
0.5		0.00%	0.00%	0.00%	6.06%
1.0	Mild	3.03%	3.03%	12.50%	6.06%
1.5		9.09%	9.09%	12.50%	18.18%
2.0	Moderate	18.18%	39.39%	34.38%	36.36%
2.5		24.24%	18.18%	12.50%	18.18%
3.0	Moderate/Severe	27.27%	21.21%	21.88%	12.12%
3.5		12.12%	3.03%	6.25%	3.03%
4.0	Severe, pronounced bags, puffy appearance	6.06%	6.06%	0.00%	0.00%
Mean Score		2.6	2.4	2.2	2.0
Mean % Change			-8.67%	-16.55%	-23.12%
		p	0.000*	0.000*	0.000*
		t	4.629	6.535	8.916

Decrease = Improvement

*Statistically Significant (p<0.050)

**N=32 (one participant missed visit)

Expert Grading Summary Continued					
Parameter 3: Fine Lines/Wrinkles (Peri-Orbital) (N=31)					
Grading Scale		Grade Frequency			
		Baseline	Immediate	Week 4**	Week 6
0.0	Absence of fine lines	0.00%	0.00%	0.00%	0.00%
0.5		0.00%	0.00%	0.00%	0.00%
1.0	Slightly visible fine lines	0.00%	0.00%	0.00%	0.00%
1.5		0.00%	3.23%	16.67%	29.03%
2.0	Clearly visible fine lines and/or wrinkles	32.26%	32.26%	26.67%	16.13%
2.5		25.81%	22.58%	13.33%	12.90%
3.0	Prominent wrinkles	16.13%	16.13%	16.67%	19.35%
3.5		12.90%	12.90%	13.33%	12.90%
4.0	Deep, Severe lines wrinkles	12.90%	12.90%	13.33%	9.68%
Mean Score		2.7	2.7	2.6	2.5
Mean % Change			-1.18%	-4.57%	-8.82%
p			0.161	0.001*	0.000*
t			1.438	3.513	5.303

Decrease = Improvement

*Statistically Significant ($p < 0.050$)

**N=32 (one participant missed visit)

Cutometer Summary (N=29) Skin Firmness (R0)								
No.	MRN	Baseline	Immediate**	% Change	Week 4	% Change	Week 6	% Change
<p>Participant-level rows removed from this public edition.</p> <p>Aggregate Mean, p, and t rows remain unchanged below.</p>								
Mean	0.2872	0.2633	-8.31%	0.3791	32.00%	0.3882	35.17%	
	P	0.039*		0.000*		0.000*		
	t	2.174		6.356		7.843		

Decrease = Improvement

*Statistically Significant (p<0.050)

**N=27 (due to instrument malfunction)

Cutometer Summary (N=29) Skin Elasticity (R5)								
No.	MRN	Baseline	Immediate**	% Change	Week 4	% Change	Week 6	% Change
<p>Participant-level rows removed from this public edition.</p> <p>Aggregate Mean, p, and t rows remain unchanged below.</p>								
Mean	0.4620	0.5320	15.16%	0.3893	-15.74%	0.4064	-12.04%	
	P	0.001*		0.000*		0.005*		
	t	3.931		4.531		3.052		

Increase = Improvement

*Statistically Significant (p<0.050)

**N=27 due to instrument malfunction

18. Conclusion:

Test material **Neotight Revitalizing Eye Serum** (VCS Sample No.: SA211001; VCS Clinical Study No.: CS201061) tested under conditions stated herein, demonstrated the following:

After 8 hours post single application, the majority of subjects (>50%) responded favorably to 20 out the 21 statements regarding the product and its effects on the condition and appearance of their skin via questionnaire. At 4 and 6 weeks, positive perception of the effects of the product continued with all 17 questions having favorable responses.

Immediate, statistically significant improvement from Baseline mean scores was observed for the appearance of Under Eye Discoloration/Dark Circles and Under Eye Puffiness. Significance from Baseline continued through Week 4 and 6. Statistically significant improvements from Baseline were also observed for Fine Lines/Wrinkles at Week 4 and Week 6.

Cutometer results showed a statistically significant mean improvement relative to Baseline for skin firmness and elasticity immediately post single application. No improvement was noted after 4 or 6 weeks.

All individual listings are provided in Appendix II. Images are provided separately.

19. Authorization:


ZORRO SIGN 7441C26F05

ANNA HARDY

Principal Investigator

CLINICAL RESEARCH MANAGER

04/08/2021

DATE



ZORRO SIGN 7441C26F10

JAMES VANZETTA, A.S.

Technical Personnel

DIRECTOR: Clinical Photography

04/08/2021

DATE



ZORRO SIGN 7441C26F20

CHRYSTAL PLANETA, B.S.

Technical Personnel

SENIOR CLINICAL TECHNICIAN: Claims & Efficacy

04/08/2021

DATE



ZORRO SIGN 7441C26F30

SURINA CHOCK

Technical Personnel

CLINICAL TECHNICIAN: Claims & Efficacy

04/09/2021

DATE

In addition to review by the Principal Investigator and study personnel, the report has been reviewed by the Medical Investigator.

David Wrone
zorrosign 7441C26F55

DAVID A. WRONE, M.D.
Dermatologist
MEDICAL INVESTIGATOR

04/09/2021

DATE

20. Quality Assurance Statement:

The Quality Assurance and Quality Control Department (QA/QC) at Validated Claim Support, LLC is independent of the employees involved in the investigation. The QA/QC unit is responsible for overseeing essential study documentation and, if requested by a Sponsor, monitoring study conduct.

This statement confirms that the study is conducted in accordance with the Good Clinical Practices and other applicable laws and regulations, as well as VCS Standard Operating Procedures and approved study protocol (where applicable).

The Quality Department ensures this report accurately reflects data collected during the study.



Kornelia Grzybowska
zorrosign 7441C26F69

KORNELIA GRZYBOWSKA, M.S.
Quality Assurance
DIRECTOR: Quality

04/09/2021

DATE

Bibi Tasmiya Masud
zorrosign 7441C26F7D

BIBI TASMIYA MASUD, B.A.
Quality Control
MANAGER: Quality

04/09/2021

Date